GSK’s Bepirovirsen Nears Functional Cure for Chronic Hepatitis B After Successful Phase 3 Trials
GSK’s bepirovirsen achieved its primary endpoint in late-stage clinical trials, potentially offering an alternative to lifelong antiviral treatments for patients with chronic hepatitis B infection. This development marks a significant step toward a functional cure for the disease.
Overview
GSK's antisense oligonucleotide bepirovirsen has met the main goal in two Phase 3 clinical trials involving patients with chronic hepatitis B infection.
Key Points
- The therapy achieved functional cure rates after six months of treatment.
- It offers an alternative approach to current antiviral drugs that require lifelong use.
- The results suggest potential for improved patient outcomes and reduced treatment burdens.
Implications
If approved, bepirovirsen could transform the treatment landscape for chronic hepatitis B, providing a finite-duration therapy aimed at functional cure rather than continuous viral suppression.
Source: MedCity News
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.